Impact of omega-3 supplementation on lipoprotein-associated phospholipase A2 mass and activity: A systematic review and meta-analysis of randomized controlled trials
Simental-Mendía LE, Simental-Mendía M, Barragán-Zúñiga LJ, Aguillón-Marín P
Journal of clinical lipidology · 1 citation
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Meta-analysis (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2025-12-16 · J Clin Lipidol · vol. 20 · issue 2 · pp. 279–288
- Publisher
- Elsevier BV
- Cited
- 3 citations · more than 66% of similar papers · 0.8× the field average
- References
- 48 works
- Access
- Paywalled
- Research areas
- Fatty Acid Research and Health · Protein Kinase Regulation and GTPase Signaling · Vitamin K Research Studies
- Keywords
- Randomized controlled trial, Phospholipase A2, Meta-analysis, Clinical trial
- MeSH
- humans, 1-alkyl-2-acetylglycerophosphocholine esterase, fatty acids, omega-3, dietary supplements, randomized controlled trials as topic
4 authors
From MX
- Luis E. Simental-Mendía · correspondingMexican Social Security Institute
- Mario Simental-MendíaUniversidad Autónoma de Nuevo León
- Laura Jazel Barragán-ZúñigaDurango Institute of Technology; Autonomous University of Durango
- Paola Aguillón-MarínMexican Social Security Institute
Abstract
Background
Omega-3 polyunsaturated fatty acid (PUFA) administration has been associated with a reduced risk of developing cardiovascular diseases. Some studies have explored the potential effect of omega-3 PUFA on lipoprotein-associated phospholipase A2 (Lp-PLA2) levels with conflicting results; while some have shown no effect, others have found reduced levels of Lp-PLA2 with omega-3 supplementation. This meta-analysis of randomized controlled trials aims to clarify the impact of omega-3 supplementation on Lp-PLA2 mass and activity.
Sources of material
The Medical Subject Headings (MeSH) terms and keywords were searched in Web of Science, PubMed, Scopus, Google Scholar, and ClinicalTrials.gov databases. The random- or fixed-effects model and the generic inverse variance weighting method were applied for quantitative data. The influence of each study on the overall effect size was determined using the leave-one-out method.
Abstract of findings
The meta-analysis of 16 randomized controlled trials showed a significant reduction in Lp-PLA2 mass with omega-3 intervention (weighted mean difference [WMD]: -24.05 ng/mL, 95% CI: -27.63, -20.47, P < .0001) but no significant changes in Lp-PLA2 activity (WMD: -8.54 nmol/mL/min, 95% CI: -27.25, 10.18, P = .37). A subgroup analysis by type of omega-3 supplementation revealed that either icosapent ethyl (WMD: -32.67 ng/mL, 95% CI: -34.36, -30.98, P < .00001) or other omega-3 formulations (WMD: -17.05 ng/mL, 95% CI: -22.93, -11.18, P < .00001) significantly decreased the Lp-PLA2 mass.
Conclusion
Omega-3 supplementation significantly reduces circulating levels of Lp-PLA2 mass without affecting its activity.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.